Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 15, 2003. The report serves as a notification of a specific legal development regarding the company's pharmaceutical portfolio rather than a comprehensive financial results announcement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a litigation update and does not contain financial statements or performance metrics.
Material Changes
No material financial changes are reported in this filing. The primary update concerns the scheduling of a legal trial regarding intellectual property rights.
Guidance, Outlook, and Risks
- Legal Contingency: A trial regarding a patent challenge to the hemihydrate form of Paxil (expiring in 2006) is scheduled to commence on February 5, 2003, in the Federal District Court of the Northern District of Illinois (Chicago). The opposing party is Apotex.
- Forward-Looking Statements: GSK includes a safe harbor caution under the US Private Securities Litigation Reform Act of 1995, noting that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections.
- Risk Reference: Investors are directed to the "Cautionary factors that may affect future results" section in GSK's results announcement for the year ended December 31, 2001, for a detailed discussion of operational risks.
Investor Verification Checklist
- Verify the outcome of the Paxil hemihydrate patent trial scheduled for February 5, 2003, against Apotex.
- Review the full "Cautionary factors" section from the 2001 annual results filing for comprehensive risk exposure.
- Monitor subsequent filings for any financial impact resulting from the patent litigation.